Results 151 to 160 of about 272,512 (195)

An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN). [PDF]

Acta Neuropathol Commun, 2019
Tauziède-Espariat A, Debily MA, Castel D, Grill J, Puget S, Sabel M, Blomgren K, Gareton A, Dangouloff-Ros V, Lechapt E, Boddaert N, Varlet P.   +11 more
europepmc   +1 more source

Expanding the molecular grading criteria in IDH-mutant astrocytoma. [PDF]

Neuro Oncol
Virata MC, Samanamud J, Slocum CC, Kandoi S, Nguyen P, Savani MR, Shi DD, Sharma S, Hiya S, Maldonado-Díaz C, Clare K, Yokoda RT, Vij M, Mir E, Nishikawa Y, Umphlett M, Yong RL, Bederson JB, Silva-Hurtado TJ, Brem S, Hambardzumyan D, Snuderl M, Viapiano MS, Abdullah KG, McBrayer SK, Hatanpaa KJ, Walker JM, Tsankova NM, Richardson TE.   +28 more
europepmc   +1 more source

MYCN-driven metabolic remodelling of the tumour microenvironment in neuroblastoma: implications for stromal biology and CAF heterogeneity. [PDF]

Cancer Metastasis Rev
Shiferaw MS, Somers K, Kovacevic Z.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Analysis of candidate gene co-amplification with MYCN in neuroblastoma

European Journal of Cancer, 1997
Previous studies have revealed that the MYCN gene spans approximately 7kb, while the amplicon has been estimated to be 100 kb to 1 Mb long [1-3]. This implies that several other genes may be present on the MYCN amplicon. Such co-amplified genes could contribute to the malignant phenotype and might provide an explanation for why not all patients with ...
John Lunec, A D Pearson, H Christiansen   +2 more
exaly   +4 more sources

MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification

European Journal of Cancer, 2004
While the role of MYCN-amplification (MNA) for risk assessment in neuroblastoma is undisputed, the phenomenon of gene copy excess below the amplification threshold is rarely described. To discuss biological characteristics and the clinical impact of the so-called MYCN-gain versus amplified or non-amplified cases, we investigated the MYCN status of 659 ...
B Hero
exaly   +3 more sources

Heterogeneity of MYCN Amplification in a Child with Stroma-Rich Neuroblastoma (Ganglioneuroblastoma)

Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997
Amplification of MYCN portends rapid tumor progression and poor prognosis in neuroblastoma. MYCN copy number has been described as homogeneous within a tumor and congruent in primary tumor and metastasis. We report a child with stage III favorable histology stroma-rich neuroblastoma (ganglioneuroblastoma) and a poor outcome with an apparent change in ...
Jeremy Squire, Maria Zielenska, Paul Thörner   +2 more
exaly   +3 more sources

Heterogeneous MYCN amplification in neuroblastoma [PDF]

, 2010
Unter den 110 MYCN amplifizierten (MNA) Neuroblastomen, die in den letzten 10 Jahren am CCRI analysiert wurden, befanden sich 26 Tumore mit variierender Anzahl von Tumorzellen oder Arealen ohne MNA. In Übereinstimmung mit den Richtlinien der INRG Biologie Gruppe wurden diese Tumore als „heterogen MYCN- amplifiziert (hetMNA)“ eingestuft.
Bogen, Dominik
openaire   +2 more sources